Schedule 13D ownership disclosure
Nautilus Biotechnology, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 63909J108
Event date: 2025-01-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLCReported CIK 0001224962
Shares: 12,594,211 · Class: 10%
- Joseph EdelmanReported CIK 0001164426
Shares: 12,594,211 · Class: 10%
- Perceptive Life Sciences Master Fund, Ltd.Reported CIK 0001249675
Shares: 12,428,351 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-011961
- Form type
- SCHEDULE 13D/A
- Filer
- Nautilus Biotechnology, Inc.
- CIK
- CIK 1808805
- Filed
- Jan 31, 2025
- Reporting period
- Jan 31, 2025
- Description
- Schedule 13D beneficial ownership